BACKGROUND: Animal, epidemiologic, and human clinical studies suggest a putative role for vitamin D in osteoarthritis (OA). Inadequate sunlight exposure and lower serum levels of 25(OH)D appear in some reports to be associated with an increased risk for progression of knee OA. QUESTIONS/PURPOSES: We asked whether treatment with vitamin D would (1) reduce knee pain (WOMAC and VAS), (2) improve function (WOMAC), and (3) change levels of relevant biochemical markers in patients with knee OA with vitamin D insufficiency. METHODS: This randomized controlled pilot trial prospectively enrolled 107 patients with knee OA with vitamin D insufficiency (25(OH)D ≤ 50 nmol/L) to receiveoral vitamin D or placebo. The primary outcome measures were pain and function, and the secondary were biochemical markers. At baseline, the two groups were comparable. The patients were followed for 1 year. RESULTS: At 12 months, knee pain had decreased in the vitamin D group by mean -0.26 (95% CI, -2.82 to -1.43) on VAS and -0.55 (95% CI, -0.07 to 1.02) on the WOMAC, whereas in the placebo group, it increased by mean 0.13 (95% CI, -0.03 to 0.29) on the VAS and 1.16 (95% CI, 0.82 to 1.49) on the WOMAC (effect size = 0.37 and 0.78). Likewise knee function improved in the vitamin D group by mean -1.36 (95% CI, -1.87 to -0.85) over the placebo group which had a mean 0.69 (95% CI, -0.03 to 1.41; effect size = 0.06). There were significant biochemical changes in serum total calcium, 25(OH)D and alkaline phosphatase. CONCLUSIONS: The results above suggest there is a small but statistically significant clinical benefit to vitamin D treatment in patients with knee OA, although we recommend a long-term study to determine whether these changes are clinically important and whether they will be sustained with time. Further studies with long-term radiologic evaluations are needed.
RCT Entities:
BACKGROUND: Animal, epidemiologic, and human clinical studies suggest a putative role for vitamin D in osteoarthritis (OA). Inadequate sunlight exposure and lower serum levels of 25(OH)D appear in some reports to be associated with an increased risk for progression of knee OA. QUESTIONS/PURPOSES: We asked whether treatment with vitamin D would (1) reduce knee pain (WOMAC and VAS), (2) improve function (WOMAC), and (3) change levels of relevant biochemical markers in patients with knee OA with vitamin Dinsufficiency. METHODS: This randomized controlled pilot trial prospectively enrolled 107 patients with knee OA with vitamin Dinsufficiency (25(OH)D ≤ 50 nmol/L) to receive oral vitamin D or placebo. The primary outcome measures were pain and function, and the secondary were biochemical markers. At baseline, the two groups were comparable. The patients were followed for 1 year. RESULTS: At 12 months, knee pain had decreased in the vitamin D group by mean -0.26 (95% CI, -2.82 to -1.43) on VAS and -0.55 (95% CI, -0.07 to 1.02) on the WOMAC, whereas in the placebo group, it increased by mean 0.13 (95% CI, -0.03 to 0.29) on the VAS and 1.16 (95% CI, 0.82 to 1.49) on the WOMAC (effect size = 0.37 and 0.78). Likewise knee function improved in the vitamin D group by mean -1.36 (95% CI, -1.87 to -0.85) over the placebo group which had a mean 0.69 (95% CI, -0.03 to 1.41; effect size = 0.06). There were significant biochemical changes in serum total calcium, 25(OH)D and alkaline phosphatase. CONCLUSIONS: The results above suggest there is a small but statistically significant clinical benefit to vitamin D treatment in patients with knee OA, although we recommend a long-term study to determine whether these changes are clinically important and whether they will be sustained with time. Further studies with long-term radiologic evaluations are needed.
Authors: Laura L Laslett; Stephen Quinn; John R Burgess; Venkateswaran Parameswaran; Tania M Winzenberg; Graeme Jones; Changhai Ding Journal: Ann Rheum Dis Date: 2013-04-17 Impact factor: 19.103
Authors: Arjan P Bergink; André G Uitterlinden; Johannes P T M Van Leeuwen; Cok J Buurman; Albert Hofman; Jan A N Verhaar; Huibert A P Pols Journal: J Clin Rheumatol Date: 2009-08 Impact factor: 3.517
Authors: T L Glover; B R Goodin; A L Horgas; L L Kindler; C D King; K T Sibille; C A Peloquin; J L Riley; R Staud; L A Bradley; R B Fillingim Journal: Arthritis Rheum Date: 2012-12
Authors: S Muraki; E Dennison; K Jameson; B J Boucher; T Akune; N Yoshimura; A Judge; N K Arden; K Javaid; C Cooper Journal: Osteoarthritis Cartilage Date: 2011-08-16 Impact factor: 6.576
Authors: D T Felson; R C Lawrence; P A Dieppe; R Hirsch; C G Helmick; J M Jordan; R S Kington; N E Lane; M C Nevitt; Y Zhang; M Sowers; T McAlindon; T D Spector; A R Poole; S Z Yanovski; G Ateshian; L Sharma; J A Buckwalter; K D Brandt; J F Fries Journal: Ann Intern Med Date: 2000-10-17 Impact factor: 25.391
Authors: Toni L Glover; Burel R Goodin; Christopher D King; Kimberly T Sibille; Matthew S Herbert; Adriana S Sotolongo; Yenisel Cruz-Almeida; Emily J Bartley; Hailey W Bulls; Ann L Horgas; David T Redden; Joseph L Riley; Roland Staud; Barri J Fessler; Laurence A Bradley; Roger B Fillingim Journal: Clin J Pain Date: 2015-12 Impact factor: 3.442
Authors: Debbie L Matossian-Motley; Diane A Drake; John S Samimi; Carlos A Camargo; Sadeq A Quraishi Journal: JPEN J Parenter Enteral Nutr Date: 2014-10-14 Impact factor: 4.016
Authors: Gabby B Joseph; Charles E McCulloch; Michael C Nevitt; Jan Neumann; John A Lynch; Nancy E Lane; Thomas M Link Journal: Arthritis Care Res (Hoboken) Date: 2020-09 Impact factor: 4.794
Authors: Alexandra Beling; M Timothy Hresko; Leah DeWitt; Patricia E Miller; Sarah A Pitts; John B Emans; Daniel J Hedequist; Michael P Glotzbecker Journal: Spine Deform Date: 2021-03-08